SKIBSTED RUSSELL 4

What Happened
Russell Skibsted, Chief Financial Officer of Processa Pharmaceuticals (PCSA), reported an open-market purchase (code P) of 1,984 shares on May 15, 2026 at $2.97 per share, for a total cost of $5,892. This was a purchase (a net acquisition), which insiders sometimes view as more informative than routine sales.

Key Details

• Transaction date: 2026-05-15; Price: $2.97 per share; Shares acquired: 1,984; Total value: $5,892.
• Form filed: Form 4 filed with the SEC on 2026-05-19 (within the two-business-day reporting window).
• Shares owned after transaction: Not disclosed in the provided filing data.
• Footnote: F1 corrects immaterial errors on a prior Form 4 (filed May 1, 2026) — the April 30, 2026 purchase price was corrected to $2.71 (not $2.69), reducing that earlier reported purchase by 16 shares.
• Transaction code: P = purchase (open market or private purchase).

Context
This report documents a small open-market purchase by a company executive. Purchases by insiders can signal confidence, but they are only one data point; no inference about motivation should be made from this single transaction. The filing appears timely and the footnote reflects a minor correction to a prior filing.